Merck And Co INC New (MRK) Position Held by Vaughan David Investments Inc

March 20, 2018 - By Adrian Erickson

Investors sentiment decreased to 1.06 in 2017 Q3. Its down 0.01, from 1.07 in 2017Q2. It is negative, as 46 investors sold MRK shares while 619 reduced holdings. 106 funds opened positions while 598 raised stakes. 1.96 billion shares or 0.47% more from 1.95 billion shares in 2017Q2 were reported. Donaldson Capital Mngmt Lc owns 32,213 shares. Cheviot Value Mgmt Lc has 54,348 shares for 1.89% of their portfolio. Logan Capital Management has invested 0.56% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Ironwood Invest Mngmt Ltd Llc reported 5,459 shares. Moreover, Pettyjohn Wood White has 0.86% invested in Merck & Co., Inc. (NYSE:MRK) for 36,182 shares. Park National Oh has invested 1.55% in Merck & Co., Inc. (NYSE:MRK). Teachers Insurance And Annuity Association Of America owns 0.28% invested in Merck & Co., Inc. (NYSE:MRK) for 159,322 shares. Aviance Prtn Lc accumulated 15,564 shares or 0.34% of the stock. Sei Invests Com stated it has 0.28% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Barrow Hanley Mewhinney Strauss Limited Liability Company holds 15.12 million shares or 1.46% of its portfolio. Glg Ltd Liability owns 144,693 shares for 0.6% of their portfolio. Wills Fincl Incorporated invested 1.15% in Merck & Co., Inc. (NYSE:MRK). New York State Teachers Retirement Sys owns 4.73M shares. Mcdaniel Terry Co owns 3,408 shares. 1.41M were reported by Comerica Commercial Bank.

Vaughan David Investments Inc increased its stake in Merck And Co Inc New (MRK) by 1601.44% based on its latest 2017Q3 regulatory filing with the SEC. Vaughan David Investments Inc bought 615,240 shares as the company’s stock declined 2.46% while stock markets rallied. The institutional investor held 653,658 shares of the health care company at the end of 2017Q3, valued at $48.69M, up from 38,418 at the end of the previous reported quarter. Vaughan David Investments Inc who had been investing in Merck And Co Inc New for a number of months, seems to be bullish on the $146.97 billion market cap company. The stock decreased 0.22% or $0.12 during the last trading session, reaching $54.51. About 1.89 million shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 16.86% since March 20, 2017 and is uptrending. It has outperformed by 0.16% the S&P500.

Vaughan David Investments Inc, which manages about $1.81B and $2.04 billion US Long portfolio, decreased its stake in Johnson & Johnson (NYSE:JNJ) by 112,518 shares to 175,603 shares, valued at $20.67M in 2017Q3, according to the filing. It also reduced its holding in Intel Corporation (NASDAQ:INTC) by 785,620 shares in the quarter, leaving it with 159,976 shares, and cut its stake in Procter & Gamble Co (NYSE:PG).

More recent Merck & Co., Inc. (NYSE:MRK) news were published by: which released: “Eisai clinches Merck deal to develop and sell cancer drug, shares soar” on March 07, 2018. Also published the news titled: “Massachusetts court: Merck can be sued over generic drug injury” on March 16, 2018.‘s news article titled: “Merck: A True Value Play?” with publication date: March 10, 2018 was also an interesting one.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Among 24 analysts covering Merck & Co. Inc. (NYSE:MRK), 18 have Buy rating, 0 Sell and 6 Hold. Therefore 75% are positive. Merck & Co. Inc. has $7400 highest and $50 lowest target. $65.28’s average target is 19.76% above currents $54.51 stock price. Merck & Co. Inc. had 81 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was maintained by Deutsche Bank on Monday, July 17 with “Hold”. Leerink Swann maintained the shares of MRK in report on Monday, October 23 with “Market Perform” rating. Morgan Stanley maintained Merck & Co., Inc. (NYSE:MRK) rating on Wednesday, February 7. Morgan Stanley has “Equal-Weight” rating and $63 target. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Hold” rating by Jefferies on Thursday, November 16. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Buy” rating by SunTrust on Tuesday, January 16. Jefferies maintained it with “Sell” rating and $5200 target in Monday, July 17 report. Jefferies downgraded the stock to “Underperform” rating in Monday, December 19 report. The rating was upgraded by Barclays Capital on Tuesday, December 1 to “Overweight”. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Outperform” rating by Credit Suisse on Monday, February 5. The rating was initiated by Berenberg on Tuesday, November 24 with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.